OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 04:47 pm EST
Share
OpGen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.448713 million compared to USD 1.24 million a year ago. Net loss was USD 14.1 million compared to USD 6.06 million a year ago. Basic loss per share from continuing operations was USD 6 compared to USD 3.2 a year ago.
For the nine months, revenue was USD 1.89 million compared to USD 2.88 million a year ago. Net loss was USD 26.75 million compared to USD 27.99 million a year ago. Basic loss per share from continuing operations was USD 11.4 compared to USD 15.8 a year ago.
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Companyâs product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Companyâs subsidiaries include Curetis GmbH and Ares Genetics GmbH.
OPGEN, INC. 
